

Minneapolis Heart Institute Foundation Cardiovascular Grand Rounds

Title: What Can We Learn from the History of Defibrillation and the ICD?

Faculty: Charles Swerdlow, MD

Professor of Medicine, Smidt Heart Institute, Cedars-Sinai Medical Center
Attending Electrophysiologist, Cedars-Sinai Medical Center

Date: November 3, 2025

Time: 7:00 – 8:00 AM

Location: Minneapolis Heart Institute Building, Suite 100, MHIF Learning Center

Webinar – visit www.mplsheart.org/grandrounds for login information

OVERVIEW/PURPOSE STATEMENT

MHIF Cardiovascular Grand Rounds provides physicians and other health care providers the opportunity to review and discuss the latest developments in cardiovascular care.

OVERALL OBJECTIVES

At the completion of this activity, the participants should better be able to:

1. Identify the technologies introduced in the 20th century that enabled the development of the ICD.
2. Describe the conceptual frameworks/paradigms that delayed progress in defibrillation research and the different approaches that overcame these delays.
3. Recognize the developments in medicine, politics, and economics that shaped the course of defibrillator development.

DISCLOSURE POLICY

Allina Health, Office of Accreditation intends to provide balance, independence, objectivity, and scientific rigor in all of its educational activities. The ACCME defines an ineligible company as “any entity” whose primary business is producing, marketing, re-selling, or distributing health care products/services used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company. All faculty and planners participating in the CME activity are required to disclose to the audience any relevant financial relationships with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended and all relevant financial relationships will go through a mitigation process.

DISCLOSURE STATEMENTS

Faculty - Dr. Swerdlow has disclosed the following financial relationships with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended, as it relates to presenting their content in this CME activity: Existing: Speaker, Patent royalty payments: Medtronic. All relevant financial relationships have been mitigated.

Planner(s) - The following planners have disclosed that they DO NOT have any financial relationships with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended as it relates to planning the content of this CME activity: Ross Garberich, Dr. Kevin Harris, Maia Hendel, Dr. Kasia Hryniewicz, Dr. Carly Lodewyks, Cindy Resman, Dr. Scott Sharkey, Dr. Robert Steffen, Dr. Elliot Stephenson, Dr. Siu-Hin Wan and Dr. Edwin Zishiri.

The following members DO have relevant financial relationship to disclose with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended, as it related to planning the content of this activity: Dr. Nadira Hamid-Existing: Consultant: Abbott Structural, Vdyne, AMX Medical Technologies, 4C Medical Technologies, Edwards Lifesciences, Alleviant Medical, Philips, GE, Valcare Medical, Topaz, CroiValve; Dr. David Hurrell- Existing: Clinical Events Committee: Boston Scientific; Dr. Michael Miedema-Existing: Research (PI): Merck, Clearly; Dr. Yader Sandoval- Existing: Consultant/Speaker: Roche Diagnostics, Abbott Diagnostic, Cathworks, HeartFlow, Speaker/Research Grant: Clearly, Consultant: Phillips, GE Healthcare, Speaker: Medtronic. All relevant financial relationships have been mitigated.